Beilu Pharmaceutical
Beilu Pharmaceutical is a Beijing-based Chinese pharmaceutical company known for contrast-media injections and selected traditional Chinese medicine products.
Last updated November 4, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 2
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Beilu Pharmaceutical, also known as Beilu Pharma or simply Beilu, is a Chinese pharmaceutical company headquartered in Beijing. Established in 1992, the company developed a business centered on the research, manufacture, and sale of pharmaceutical products, with particular importance attached to contrast media used in diagnostic imaging. Its principal contrast-media products include gadobutrol injections, gadopentetate dimeglumine injections, and iohexol injections. The company also markets representative traditional Chinese medicine products such as Jiuwei Zhenxin Granules and Jinlianhua Granules. The company’s development combined pharmaceutical manufacturing with access to capital markets. Before its Shenzhen listing, Beilu Pharmaceutical was listed on the National Equities Exchange and Quotations. It received more than 66.6 million yuan in investor funding in 2008, and completed an initial public offering on the Shenzhen Stock Exchange’s ChiNext board in October 2009 under stock code 300016. The offering raised more than 300 million yuan and was underwritten by UBS. The company had reached the requirements for a ChiNext flotation in May of that year. Beilu expanded its investment and corporate-development activities after listing. In May 2016, it established an industry buyout fund with a reported target size of 610 million yuan. It also holds an equity interest in Shihe Gene, reflecting an interest in related life-science activities beyond its core marketed medicines. In 2022, the company established a wholly owned subsidiary in Hong Kong, supporting a broader international or cross-border corporate structure. Contrast media remains the company’s most visible specialization. These agents are administered to improve the visibility of organs, blood vessels, and other structures during imaging procedures such as computed tomography and magnetic-resonance examinations. Beilu’s portfolio includes both iodinated and gadolinium-based products, giving it exposure to more than one diagnostic-imaging modality. Alongside these products, its granule formulations provide a separate traditional Chinese medicine offering. According to the cited company overview, Beilu Pharmaceutical reported revenue of more than 983 million yuan in 2024. The same reference describes the company as one of the notable participants in the global contrast-media market. Its current identity is therefore that of a listed Chinese pharmaceutical manufacturer with a concentration in diagnostic imaging products, complemented by selected traditional medicines and life-science investments.
History
Beilu Pharmaceutical was founded in 1992 in China and developed as a pharmaceutical manufacturer with a particular emphasis on contrast media for diagnostic imaging. The company’s portfolio came to include gadolinium-based products, such as gadobutrol and gadopentetate dimeglumine injections, as well as the iodinated contrast agent iohexol injection. It also built a complementary traditional Chinese medicine business around products including Jiuwei Zhenxin Granules and Jinlianhua Granules. The company’s early financing supported its growth before public-market expansion. In 2008, Beilu secured more than 66.6 million yuan from investors. Prior to its Shenzhen listing, it was listed on the National Equities Exchange and Quotations. In May 2009, it was reported to have met the requirements for a listing on the Shenzhen Stock Exchange’s second board, and in October 2009 it completed its ChiNext flotation under stock code 300016. The IPO raised more than 300 million yuan and was underwritten by UBS. After becoming a listed company, Beilu continued to combine pharmaceutical operations with investment and expansion initiatives. In May 2016, it established an industry buyout fund valued at 610 million yuan. The company also acquired an equity stake in Shihe Gene, indicating participation in related biotechnology or life-science activities. In 2022, Beilu created a wholly owned subsidiary in Hong Kong, broadening its corporate structure beyond mainland China. The company’s financial and operating profile remained tied to pharmaceuticals and contrast media. Its reported net profit exceeded 118 million yuan in 2017, and a 2020 capital-raising event was reported at 70.42 million US dollars. The cited overview states that revenue exceeded 983 million yuan in 2024. Beilu is described as one of the important participants in the global contrast-media market, although the available reference material does not provide a detailed geographic breakdown of sales, manufacturing sites, or current management.
- 2024
Revenue exceeds 983 million yuan
[1]The cited overview reports revenue of more than 983 million yuan for 2024.
- 2022
Hong Kong subsidiary established
[1]Beilu Pharmaceutical established a wholly owned subsidiary in Hong Kong.
- 2020
Capital raising
[1]The company raised a reported 70.42 million US dollars.
- 2017
Reported net profit exceeds 118 million yuan
[1]The company’s reported net profit exceeded 118 million yuan for the year.
- 2016
Industry buyout fund established
[1]Beilu established an industry buyout fund with a reported value of 610 million yuan.
- 2009
ChiNext initial public offering
[1]Beilu Pharmaceutical raised more than 300 million yuan in its IPO and began trading on the Shenzhen Stock Exchange’s ChiNext market under ticker 300016.
- 2008
Pre-IPO investor financing
[1]The company secured more than 66.6 million yuan in financing from investors.
- 1992
Company founded
[1]Beilu Pharmaceutical was established in China.
Products and positioning
A listed Chinese pharmaceutical manufacturer with a strong focus on diagnostic contrast media, supported by a smaller portfolio of traditional Chinese medicine products and related life-science investments.
Gadolinium-based magnetic-resonance contrast media
Gadobutrol injections
Gadobutrol injection is a gadolinium-based contrast product used to enhance the visibility of anatomical structures during magnetic-resonance imaging. It is one of Beilu Pharmaceutical’s principal diagnostic-imaging products and reflects the company’s specialization in contrast media.
Gadolinium-based magnetic-resonance contrast media
Gadopentetate dimeglumine injections
Gadopentetate dimeglumine injection is a gadolinium-based contrast agent used in magnetic-resonance imaging. It forms part of Beilu’s portfolio of imaging medicines and contributes to the company’s presence in the diagnostic contrast-media market.
Iodinated contrast media
Iohexol injections
Iohexol injection is an iodinated contrast product used to improve visualization in diagnostic imaging procedures. Its inclusion gives Beilu Pharmaceutical exposure to contrast-media applications beyond magnetic-resonance imaging, including procedures that use X-ray or computed tomography technologies.
Traditional Chinese medicine
Jiuwei Zhenxin Granules
Jiuwei Zhenxin Granules are identified as one of Beilu Pharmaceutical’s representative traditional Chinese medicine products. The product complements the company’s contrast-media business and demonstrates that its marketed portfolio is not limited to diagnostic-imaging medicines.
Traditional Chinese medicine
Jinlianhua Granules
Jinlianhua Granules are another representative traditional Chinese medicine offering associated with Beilu Pharmaceutical. Available reference material identifies the product but does not provide sufficient detail on its formulation, indications, launch date, or current sales footprint.
Controversies
2025
Selected Iopamidol in Centralized Procurement Rated Dishonest by Hebei for Late Delivery
Beilu Pharmaceutical's selected product in the seventh national centralized procurement, iopamidol injection, was not delivered in a timely or adequate manner in Hebei. In June 2025, the Hebei Medical Drugs and Devices Centralized Procurement Center notified seven pharmaceutical companies including Livzon Group and Beilu Pharmaceutical and rated them at the "general" dishonesty level. The dishonesty rating may lead to reminders, risk warnings and listing restrictions, with appeal and repair possible.
Brand decisions
2022
Establish a Hong Kong subsidiaryStrategyBackground
The company pursued a broader corporate structure with an entity outside mainland China.
Action taken
Beilu Pharmaceutical established a wholly owned subsidiary in Hong Kong.
Aftermath
The available material does not detail the subsidiary’s activities, investments, or commercial contribution.
2016
Establish an industry buyout fundM&ABackground
Beilu Pharmaceutical expanded its corporate-development and investment activities after becoming a listed company.
Action taken
The company established an industry buyout fund with a reported size of 610 million yuan.
Aftermath
The available reference does not specify the fund’s completed acquisitions, investment returns, or subsequent operating impact.
Buyout fund size. 610 million yuan (2016)
2009
Proceed with a ChiNext public listingStrategyBackground
After earlier financing and a period on the National Equities Exchange and Quotations, Beilu Pharmaceutical sought access to a larger public-market funding base.
Action taken
The company completed its initial public offering on the Shenzhen Stock Exchange’s ChiNext market in October 2009 under stock code 300016, raising more than 300 million yuan.
Aftermath
The listing provided Beilu with publicly traded status and a platform for subsequent investment and expansion activities.
IPO proceeds. More than 300 million yuan raised (2009 IPO)
Recent events
Reported
Beilu Pharma announces proposed acquisition of control of Haichang Pharma[4]
Beilu Pharma announced that it had signed a share transfer agreement with a Haichang Pharma shareholder to acquire 1.5 million shares for RMB 18 million. If completed, the transaction would give Beilu Pharma a 37.91% stake and make it Haichang Pharma’s controlling shareholder.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/beilu-pharmaceutical · Editorial policy · How profiles are compiled